Brazilian national health surveillance agency publishes new rules on clinical trials for drug marketing authorization
Summary On December 2, 2024, the Brazilian National Health Surveillance Agency (ANVISA) published the Resolution (RDC) no. 945/2024, establishing new guidelines and procedures for conducting clinical trials in Brazil aimed at granting drug marketing authorization. The new rule proposes an alignment of the matter with Federal Law no. 14.874/2024 and the reductions of bureaucratic barriers […]